Quick Facts

Dr. Marty Ross, MD
Dr. Ross's Expert Review
Boluoke is the brand of lumbrokinase I have used the longest in my practice. Lumbrokinase is a group of fibrin-dissolving enzymes extracted from earthworms, and Boluoke standardizes each acid-resistant capsule to 20 mg of enzyme at 300,000 lumbrokinase units. The capsule design matters. Lumbrokinase can be inactivated by stomach acid, so these capsules are built to dissolve in the small intestine instead.
Where it fits
Three things come up again and again in my conversations with patients: circulation that feels sluggish, biofilm-related concerns and possible fibrin-germ nests. Fibrin is a protein the body uses for clotting, and it is also described in the literature as a scaffold that germs can hide in. Using fibrin, germs can hide in biofilms and in fibrin-germ nests. Lumbrokinase supports the body’s natural breakdown of fibrin. That is why I use Boluoke as part of broader wellness regimens; the working idea is that supporting healthy fibrin balance lets the rest of a regimen do its job.
The research
The enzyme was first extracted and characterized from Lumbricus rubellus in the 1990 paper by Mihara and colleagues, and proteomic work has since identified the specific enzymes responsible. A 2023 study found lumbrokinase supports fibrin breakdown without activating plasminogen, a detail the study authors highlight. Much of the clinical data is older hospital work, and the newer trials in chronic illness are still underway. I am candid about that gap and lean on mechanism plus what I see in practice.
How I approach dosing
One capsule one to two times a day on an empty stomach is my usual starting point. For more pronounced circulation concerns I have used 2 capsules two times a day. The manufacturer lists a child dose of 1 capsule per 17 pounds of body weight per day, something I only consider with the child’s physician on board. This is not for people with bleeding risks, before surgery, or during pregnancy, and anyone on blood thinners needs physician supervision.
The bottom line
Enzymes are tools, not stand-alone treatments. Used well, inside a full regimen, Boluoke is a dependable tool for fibrin-germ nests and biofilm support.
How I Use It in My Practice
Boluoke earns its place in my regimens for biofilms and fibrin-germ nests. I start most people at 1 capsule once a day on an empty stomach, then move toward 2 times a day as tolerated. When circulation concerns are more pronounced, I have used 2 capsules two times a day. For children I follow the manufacturer scale of 1 capsule per 17 pounds of body weight per day, and only with the child’s physician involved. I stop it one week before any planned surgery and restart only with the surgeon’s agreement. I do not combine it with other enzyme supplements, since the manufacturer warns other enzymes can break lumbrokinase down. People on blood thinners or anti-platelet medicines review it with their prescribing physician first. When temporary reactions come up after starting, I hold the dose steady or step back before climbing again.
The Research, in Dr. Ross's Words
Lumbrokinase has one of the cleaner mechanistic research bases in this category. The original 1990 paper by Mihara and colleagues isolated the fibrin-dissolving enzymes from Lumbricus rubellus and showed they break down fibrin on both plasminogen-rich and plasminogen-free plates, which means the enzymes act on fibrin directly rather than through the body’s plasmin system. Later proteomic work confirmed the specific enzymes responsible and their high fibrinolytic activity.
A 2023 study adds a useful detail. In that study, lumbrokinase prevented intra-abdominal adhesions by inhibiting fibroblast migration, again without converting plasminogen into plasmin, a point the authors raise. A 2024 review of earthworm-derived bioactive agents summarizes the fibrinolytic and antithrombotic properties reported across the literature, and a review of recombinant production methods shows how much effort goes into making this enzyme reliably. That tells me the activity is real and reproducible. It does not tell me how well it performs in sick patients.
What the published papers do not yet give us is strong controlled human trial data in the chronic conditions my patients care about. The newer clinical trials in post-treatment Lyme and related conditions are still underway. In my read of this research, the enzyme science is solid, the plasminogen-independent action is a point in its favor, and the clinical outcomes remain to be proven. That is exactly how I present it to patients.
References
Supplement Facts
| Amount Per Serving | Amount | |
|---|---|---|
Proprietary earthworm protein extract Containing 300,000 LK units | 20 mg | |
*Daily Value not established. | ||

















